Overview

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Status:
Terminated

Trial end date:
2019-01-08

Target enrollment:

Participant gender:

Summary

Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine the recommended Phase II dose of the combination.

Phase:

Phase 1

Details

Lead Sponsor:

Pamela Munster
University of California, San Francisco

Collaborator:

QuantumLeap Healthcare Collaborative

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Talazoparib